Related Experiment Video
Updated: Feb 17, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Synthetically lethal nanoparticles for treatment of endometrial cancer
Kareem Ebeid1, Xiangbing Meng2,3, Kristina W Thiel2
1Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.
Abstract:
Uterine serous carcinoma, one of the most aggressive types of endometrial cancer, is characterized by poor outcomes and mutations in the tumour suppressor p53. Our objective was to engender synthetic lethality to paclitaxel (PTX), the frontline treatment for endometrial cancer, in tumours with mutant p53 and enhance the therapeutic efficacy using polymeric nanoparticles (NPs). First, we identified the optimal NP formulation through comprehensive analyses of release profiles and cellular-uptake and cell viability studies. Not only were PTX-loaded NPs superior to PTX in solution, but the combination of PTX-loaded NPs with the antiangiogenic molecular inhibitor BIBF 1120 (BIBF) promoted synthetic lethality specifically in cells with the loss-of-function (LOF) p53 mutation. In a xenograft model of endometrial cancer, this combinatorial therapy resulted in a marked inhibition of tumour progression and extended survival. Together, our data provide compelling evidence for future studies of BIBF- and PTX-loaded NPs as a therapeutic opportunity for LOF p53 cancers.
Insights
This study developed nanoparticle-delivered paclitaxel (PTX) and BIBF 1120 combination therapy. This approach shows synthetic lethality in uterine serous carcinoma with mutant p53, improving treatment efficacy.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Uterine serous carcinoma (USC) is an aggressive endometrial cancer subtype.
- Poor prognosis is linked to loss-of-function (LOF) p53 mutations.
- Current treatments for USC have limited efficacy in patients with p53 mutations.
Purpose of the Study:
- To develop a synthetic lethality strategy for paclitaxel (PTX) in p53-mutated USC.
- To enhance therapeutic efficacy using polymeric nanoparticles (NPs).
- To evaluate a combination therapy of PTX-loaded NPs and BIBF 1120.
Main Methods:
- Formulation and characterization of PTX-loaded polymeric NPs.
- In vitro studies assessing NP release, cellular uptake, and viability.
- In vivo evaluation in a USC xenograft model.
Main Results:
- PTX-loaded NPs demonstrated superior efficacy compared to PTX in solution.
- The combination of PTX-loaded NPs and BIBF 1120 induced synthetic lethality in p53-mutated USC cells.
- Combinatorial therapy significantly inhibited tumor progression and extended survival in vivo.
Conclusions:
- Polymeric nanoparticles offer an effective delivery system for USC therapy.
- Combined PTX-NPs and BIBF 1120 represent a promising therapeutic strategy for p53-mutated USC.
- This approach warrants further investigation for clinical application in LOF p53 cancers.
More Related Videos
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
